Pfizer Venture Investments
Corporate VCSeed–Late Stage · 10 people tracked
Investment thesis
Strategic venture investor that preserves founder independence by not taking product rights, offers Pfizer collaboration potential, drug-discovery and business development expertise, active China strategy, and pharma exits.
Source: firm website, verified Aug 7, 2026.
Team · 10 people
from the firm's website & public directories
What they invest in
from 97 of 186 portfolio companiesBiotech ×88Healthtech ×53Medical Devices ×24Deep Tech ×18AI & Machine Learning ×15Digital Health ×6Longevity ×3SaaS ×3
HQs:United States×43Belgium×2Switzerland×2Azerbaijan×1Germany×1France×1
Investments · 186 tracked
founders shown can be your intro pathBy year:2024 · 12022 · 12019 · 12018 · 12017 · 12016 · 12015 · 17 dated
BiotechEmeryville, US
David Kirn(Executive Officer, Director)David Schaffer(Director)Theresa Janke(Executive Officer)
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsChiesi Ventures
Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells.
Co-investorsRA CapitalVivo CapitalNan Fung Life SciencesNovo HoldingsPivotal Life SciencesSofinnova Ventures
Enliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML).
BiotechHealthtech
Co-investors5AM VenturesOrbiMedRoche Venture Fund
Ginkgo Bioworks builds autonomous labs and offers cell-programming and bioengineering services for the biopharma, agriculture, and industrial biotech markets.
AgTechAI & Machine LearningBiotechDeep TechHealthtechBoston, US
Jason Kelly(Founder)inAustin Che(Founder)inTom Knight(Founder)inBarry Canton(Founder)inReshma Shetty(Founder)in
BoardReshma Sohoni
Co-investors11.2 CapitalB3 HoldingCannage CapitalCool Climate CollectiveDCVC (Data Collective)Designer Fund+15 more
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersNextech InvestSanofi Ventures+2 more
Co-investorsBay City CapitalCanaan Partners
Novocure is a global oncology company developing Tumor Treating Fields therapies, including its Optune Pax device, to treat aggressive cancers such as locally advanced pancreatic cancer.
BiotechHealthtechMedical Devices
Co-investorsWindham Capital Partners
BiotechBoston, US
Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)
BoardEdward T. Mathers(Director)inJonathan Silverstein(Director)inNeil Exter(Director)inTodd Foley(Director)
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)OrbiMedThird Rock Ventures
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)
Co-investorsAtlas VentureNSG VenturesSofinnova VenturesSolasta VenturesNew Enterprise Associates (NEA)OrbiMed
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Timothy Mayer(Executive Officer)Michael Richman(Executive Officer, Director)Elaine V. Jones(Director)Udayan Guha(Executive Officer)Anne Borgman(Director)Steven P. Cobourn(Executive Officer)
Co-investorsCanaan PartnersLAVLilly Asia VenturesQuan CapitalSofinnova VenturesTaiho Ventures, LLC+1 more
RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.
BiotechHealthtechMedical DevicesHayward, US
Board seatRana Al-Hallaq· per SEC Form D
Co-investorsAscension VenturesCatalio Capital Management, LPSofinnova PartnersSonder CapitalSonder Futures
AMRA Medical provides MRI-based body composition analytics that generate fat and muscle biomarkers for clinical trials and clinical decision-making.
AI & Machine LearningHealthtechMedical Devices
Co-investorsHealthCap
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.
BiotechBasel, CH
Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in
Co-investorsNovartis Venture FundPontifax Venture Capital
Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.
ConsumerGamingBaku, AZ
Co-investorsAtlas VentureMission BiocapitalPfizer Ventures
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesNextech InvestOUP (Osage University Partners)venBio Partners+1 more
Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043).
BiotechHealthtech
Co-investorsAndera PartnersM VenturesNovartis Venture FundRA CapitalSofinnova PartnersSV Health Investors
Co-investorsSV Health Investors
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)John Borkholder(Executive Officer)
BoardKristina Burow(Director)inThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersSamsara BioCapitalNewpath Partners
Co-investorsBioAdvanceOUP (Osage University Partners)
Developing bispecific antibodies for precision autoimmune applications
Co-investorsPathway Bioventures
BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions.
BiotechHealthtech
Co-investorsManta Ray VenturesMIG Capital AGOnsight Ventures
BiotechSouth San Francisco, US
Wendye Robbins(Executive Officer, Director)
BoardLuke Evnin(Director)inCameron Wheeler(Director)Peter van Vlasselaer(Director)Elaine Jones(Director)William Slattery(Director)
Co-investorsBay City CapitalOUP (Osage University Partners)+ND CapitalMPM BioImpact
BiotechSan Diego, US
Adrian Bot(Executive Officer)Laura Shawver(Executive Officer, Director)Ramin Farzaneh-Far(Executive Officer)Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)
Co-investorsRA Capital
Molecular diagnostics company offering clinical PCR systems using automation and microfluidics; acquired by QIAGEN in September 2020.
BiotechHealthtechAlbuquerque, US
Thomas Duensing(Executive Officer)Dennis Hynson(Executive Officer)Janette Phi(Executive Officer)R. Terry Dunlay(Executive Officer, Director)Sundaresh Brahmasandra(Executive Officer)Jeffrey Williams(Executive Officer, Director)
Co-investors1315 Capital1s1 EnergyABAN.VCAdBio partnersAdjuvoAgile Capital+118 more
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)Jeffrey Verboon(Founding Scientist, Computational Biology)Ansu Satpathy(Founder)Kevin Parker(Chief Executive Officer)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)
Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILWing+6 more
Co-investorsFrazier Life Sciences
BiotechPittsburgh, US
Joshua M. Tarnoff(Executive Officer, Director)Diane Jorkasky(Chief Medical Officer)Federica O'Brien(Chief Financial Officer)Hironori Hozoji(Director)
BoardI. Wistar Morris(Director)Kenji Harada(Director)
Co-investorsAndera PartnersNew Enterprise Associates (NEA)
Co-investorsDolby Family Ventures
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsMPM BioImpactPfizer VenturesPolaris PartnersTaiho Ventures, LLC
Curve Therapeutics is a drug discovery company that uses a proprietary gene-encoded, high-throughput intracellular platform to screen libraries of cyclic peptides inside live mammalian cells.
AI & Machine LearningBiotechDeep Tech
Co-investorsEpidarex CapitalColumbus Venture Partners
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.
BiotechHealthtech
Sean A. McCarthy(Chief Executive Officer and Chairman)Marcia P. Belvin(SVP, Chief Scientific Officer)Dawn Benson(SVP, Quality and Product Manufacturing)Wayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)Chris Ogden(Chief Financial Officer)
Co-investorsCanaan PartnersLongitude CapitalOrbiMed
DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.
BiotechHealthtechCambridge, US
Nenad Grmusa(Chief Executive Officer)John McCabe(Chief Financial and Operating Officer)
Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersLongwood FundUTokyo Innovation Platform Co. Ltd.Insight Partners+1 more
Acquired by Fluidigm/Standard BioTools.
Co-investorsFACIT (Fight Against Cancer Innovation Trust)
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalOUP (Osage University Partners)US Venture PartnersSofinnova Ventures
BiotechSanta Clara, US
Jeffrey Glenn(Director)David Cory(Executive Officer, Director)
BoardNina Kjellson(Director)inEd Engleman(Director)
Co-investorsCanaan PartnersVivo Capital
Co-investorsM VenturesRA Capital
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesOrbiMed
Medtronic designs and develops medical technology for treating complex diseases.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersQuesta Capital+5 more
Flare Therapeutics is a drug discovery company developing small molecule therapies that target transcription factors to restore transcriptional control disrupted by cancer.
BiotechHealthtech
Co-investorsNextech InvestShangBay Capital LLCAgent Capital
FoRx Therapeutics is a clinical-stage biotechnology company developing small-molecule drugs that target DNA replication stress in treatment-resistant cancers.
BiotechDeep TechHealthtechBasel, CH
Co-investorsNovartis Venture FundM Ventures
Genetic research and cancer detection; IPO and acquired by Exact Sciences
Co-investorsKleiner PerkinsVedanta Capital
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)Tom McCarthy(Co-founder)
Co-investorsAndera PartnersCanaan PartnersOxford Science Enterprises
Developer of antibody therapeutics targeting butyrophilin checkpoint molecules for cancer; acquired by Ipsen in 2025.
Co-investorsPureos Bioventures
Immunocodex develops tolerogenic mRNA vaccines that reprogram immune cells and rebalance the immune system to treat autoimmune diseases.
BiotechLongevity
Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.
BiotechHealthtechMedical Devices
Co-investorsBioMedPartnersLightspeed Venture PartnersMission BiocapitalPfizer Venturesredalpine
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)Dora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)
BoardTomas Kiselak(Director)
Co-investorsOUP (Osage University Partners)
Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.
Boston, US
Co-investorsAvalon BioVenturesBain Capital Life SciencesRA Capital
BiotechBoston, US
Frank G. Haluska(Executive Officer, Director)
BoardOmar Khalil(Director)Nicholas Saccomano(Director)Barbara Sosnowski(Director)Andrew Phillips(Director)Denis Patrick(Director)
BiotechNew York, US
David Pompliano(Executive Officer)David McElligott(Executive Officer, Promoter)
BoardDavid Schubert(Executive Officer, Promoter)Joel Marcus(Director)Lindsay Rayle(Executive Officer, Promoter)Barbara Dalton(Director)
Co-investorsDigitalis Ventures
BiotechNew York, US
M. Johnston Erwin(Director)Ian Howes(Executive Officer)Thong Le(Executive Officer, Director)David Schubert(Executive Officer)Kendall Mohler(Executive Officer)
BoardBarbara Dalton(Director)
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.ShangBay Capital LLCSofinnova Partners+2 more
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Ton Logtenberg(Executive Officer, Director)Mark Throsby(Executive Officer)Hui Liu(Executive Officer)John Crowley(Executive Officer)L. Andres Sirulnik(Executive Officer)Lex Bakker(Executive Officer)
Co-investorsAvoro Capital AdvisorsRA CapitalSofinnova Ventures
Co-investorsPontifax Venture Capital
BiotechKingston, US
Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)Stevin Zorn(Executive Officer, Director)Isaac Stoner(CEO)
BoardRichard G. Horan(Director)Reetika Bhardwaj(Director)
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.
BiotechHealthtech
Co-investorsRoche Venture FundSofinnova PartnersSR One Capital Management
BiotechNew York, US
Nicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)
BoardJohannes Fruehauf(Director)
Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIB
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Sofinnova PartnersPfizer Ventures
NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses.
BiotechMedical DevicesGaithersburg, US
Jonathan Schneck(Director)Alain Cappeluti(Executive Officer, Director)Kenneth Carter(Executive Officer, Director)
BoardJanis Naeve(Director)James Barrett(Director)
Co-investorsRapha Capital Management, LLC
Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Co-investorsAccess BiotechnologyBain Capital Life SciencesLightstone VenturesRA CapitalSV Health Investors
Normunity is a cancer immunotherapy company applying an immunology-based approach to identify novel anti-cancer targets at the interface of the immune system and cancer, using proprietary platforms and human cells and tissues.
AI & Machine LearningBiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)Stacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+1 more
Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T).
BiotechHealthtechWest Lafayette, US
Philip S. Low, Ph.D.(Executive Officer, Director)David Lamond(Director)Daniel Hasler(Director)Dirk Thye, M.D.(Executive Officer, Director)William J. Rutter(Director)Alex Andrianopoulos(Director)
Co-investorsBreakout VenturesElevate Ventures
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsM VenturesOxford Science EnterprisesBritish Patient CapitalJJDCPfizer Ventures
Keenova Therapeutics is a specialty pharmaceutical company developing treatments for rare, stigmatized, or unaddressed conditions across therapeutic areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care.
BiotechHealthtechMedical Devices
Co-investorsARCH Venture PartnersCross Creek AdvisorsSignet Healthcare PartnersSofinnova Ventures
BiotechCambridge, US
Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)
BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)
Co-investorsAtlas Venture
Co-investorsOUP (Osage University Partners)Sanofi Ventures
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechMedical Devices
Dr. Daniel J. Siegwart
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedSanofi Ventures+3 more
Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.
Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US
William S. Marth(Chief Executive Officer)
BoardRobert Nelsen
Co-investors8VCARCH Venture PartnersCatalio Capital Management, LPGV (Google Ventures)Koch Disruptive TechnologiesLux Capital+2 more
Saama provides AI-based data analytics solutions and services for the life sciences industry, with a focus on accelerating clinical trials.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSCampbell, US
Suresh Katta(Executive Officer, Director)Simon Ho(Executive Officer)
BoardMarc McMorris(Director)inKen Coleman(Director)Dan Fishback(Director)William Binch(Director)
Co-investorsCarrick Capital PartnersMcKesson Ventures
Co-investorsLifeforce CapitalDigitalis Ventures
Simcha Therapeutics is a clinical-stage biotech company developing protein therapeutics, with pipeline programs focused on cytokines and immunotherapies for oncology.
BiotechHealthtechNew Haven, US
Aaron Ring(Executive Officer, Director)Beatrice McQueen(Chief Operating Officer)Sanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)
Co-investorsConnecticut InnovationsAxial VCSR One Capital Management
HealthtechStamford, US
Daniel S. Lynch(Executive Officer, Director)Saqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)
BoardStephen Squinto(Director)inDeval Patrick(Director)Carl L Gordon(Director)in
Co-investorsBain Capital Life SciencesOrbiMed
QIAGEN provides sample preparation and molecular testing technologies, including automated DNA/RNA extraction, digital PCR, and syndromic testing systems.
BiotechHealthtechMedical Devices
Co-investorsHarmonic Growth PartnersYsios Capital
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.
BiotechHealthtechMedical Devices
Co-investorsFast Track InitiativeSeroba Life SciencesTaiho Ventures, LLCUTokyo Innovation Platform Co. Ltd.Cambridge Innovation CapitalM Ventures
Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.
AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US
Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)
BoardChristopher O'Donnell(Director)inDavid Rubin(Director)inJames Pavlik(Director)in
Co-investorsArboretum VenturesDeerfield Management CompanyMerck Global Health Innovation FundPfizer Ventures
Biotech decoding human tissue immune biology to create therapeutics.
Co-investorsAvego BioScience CapitalSV Health Investors
Platform company targeting selective clearance of intracellular protein aggregates in neurodegenerative disease.
Co-investorsCambridge Innovation CapitalM VenturesStart Codon
Co-investorsCTI Life Sciences Fund L.P.Sofinnova Partners
TrimTech Therapeutics develops a portfolio of targeted protein degraders, called TRIMTACs and TRIMGLUEs, that selectively remove toxic protein aggregates.
BiotechDeep Tech
Co-investorsCambridge Innovation Capital
4D Molecular Therapeutics develops genetic medicines using a directed-evolution vector platform to create customized AAV vectors optimized for specific diseases.
BiotechHealthtech
Co-investorsAmzak HealthBerkeley CatalystBOLD Longevity
Ablexis develops the AlivaMab Mouse, a transgenic platform used to discover and develop antibody and antibody-derivative drug candidates.
BiotechDeep Tech
Co-investorsCalifornia Technology Ventures
Adapsyn applies artificial intelligence and computational omics methods to natural product drug discovery, using machine learning for biological activity prediction and de novo drug design.
AI & Machine LearningBiotechDeep Tech
Co-investorsGenesys Capital
Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.
BiotechHealthtechLongevity
Benjamin Wolozin(CSO & Co-founder)
Co-investorsTCG CrossoverM Ventures
Autifony Therapeutics develops ion channel-based medicines, focused on Kv3 potassium channel modulators, to treat rare central nervous system disorders such as Fragile X syndrome and rare epilepsy syndromes.
BiotechHealthtech
Co-investorsTectonic Ventures
BioAtla develops antibody-based cancer therapeutics using its Conditionally Active Biologics (CAB) platform, which produces antibodies and other biologics that can be activated or inactivated under specific physiological conditions to improve safety and efficacy.
BiotechHealthtech
BioNTech develops immunotherapies that use the body's immune system to treat cancer, infectious diseases, and other serious illnesses.
BiotechHealthtech
Co-investorsHM Venture PartnersSalvia
BlueLight Therapeutics uses a proprietary platform based on Second Harmonic Generation (SHG) to measure real-time structural changes of biomolecules, applying this structure-driven approach to discover and develop therapeutic molecules for difficult-to-drug, high-value targets.
BiotechDeep TechSouth San Francisco, US
Co-investors5AM VenturesPfizer Ventures
AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.
BiotechHealthtechMedical Devices
Co-investorsSofinnova VenturesVida Ventures
Enara Bio is a biopharmaceutical company developing cancer immunotherapies for solid tumors, using its EDAPT platform to discover novel tumor-specific "Dark Antigens" from genomic dark matter and its EnTiCE platform to build bispecific T-cell engagers.
Biotech
Co-investorsM Ventures
Enodia Tx develops small-molecule therapies that selectively degrade disease-driving proteins at the point of synthesis by targeting the Sec61 translocon, aiming to eliminate pathogenic proteins before they mature.
BiotechDeep Tech
EvolveImmune develops trispecific T cell engagers with integrated CD2 costimulation through its EVOLVE platform to address cancer cell resistance to immunotherapies.
BiotechHealthtech
Co-investorsSolasta Ventures
G-CON manufactures prefabricated and modular cleanroom solutions, including its POD Cleanrooms, that can be installed within about six months for pharmaceutical and biotech manufacturing facilities.
Advanced ManufacturingBiotechConstruction Tech
Co-investorsWP Global Partners
Co-investorsLAVLilly Asia Ventures
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Co-investorsAndera PartnersKurma PartnersAgent Capital
Co-investorsBreakout VenturesTaiho Ventures, LLC
Co-investorsDC Investment PartnersLongwood FundQuan CapitalAgent Capital
Jnana Therapeutics operates a chemoproteomics-based drug discovery platform called RAPID to identify small molecule medicines targeting protein binding sites across multiple target classes.
BiotechDeep Tech
Co-investorsAvalon BioVentures
Kestrel Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors that target KRAS mutations across tumor types for patients with intractable cancers.
BiotechHealthtech
Co-investorsKeiretsu ForumTSVC
A biopharmaceutical company developing targeted oncology medicines, with a focus on treatments for patients of all ages including children with cancers such as pediatric low-grade glioma (pLGG).
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)DONALD BERGSTROM(Executive Officer)ANNA PROTOPAPAS(Executive Officer, Director)DAVID MOTT(Director)TIMOTHY LOWINGER(Executive Officer)EVA JACK(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime Capital PartnersLightstone VenturesNextech InvestRho Ventures
MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.
BiotechHealthtech
Co-investorsSlater Technology FundDolby Family Ventures
Co-investorsMission Bay Capital
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesPfizer VenturesVIB
Co-investorsEcoR1 Capital
Nimbus Therapeutics designs and develops small molecule medicines using computational drug design and translational medicine.
BiotechDeep Tech
Co-investorsAtlas VentureLightstone Ventures
PrescriberPoint provides prescribing tools for healthcare providers, offering FDA medication label data, drug interaction information, patient education materials, and prior authorization assistance in one platform.
Digital HealthHealthtechSaaS
Pyxis Oncology develops clinical-stage cancer therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, aimed at difficult-to-treat cancers.
BiotechHealthtech
Co-investorsLongwood FundAgent Capital
RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that detects biological signals emitted by tumors (via absorbed radiopharmaceuticals) to deliver targeted radiation to moving lung or bone tumors from primary or metastatic cancer.
BiotechHealthtechMedical DevicesHayward, US
SpringWorks is a biopharmaceutical company developing targeted oncology and rare disease therapies, including its gamma secretase inhibitor nirogacestat being evaluated in BCMA combination regimens for multiple myeloma.
BiotechHealthtech
Co-investorsFrazier Life Sciences
TRexBio develops Treg-focused biologic therapeutics for autoimmune and inflammatory diseases, using its Deep Biology Platform to analyze regulatory T cell behavior in human tissues and identify therapeutic targets.
AI & Machine LearningBiotechHealthtech
Co-investorsAvego BioScience CapitalDelos CapitalAgent Capital
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & CEO, Co-founder)
Co-investorsAtlas VentureAscenta CapitalBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesRA Capital
VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs.
BiotechCrypto & Web3Longevity
Co-investorsCollab+CurrencySora VenturesTioga Capital Partners
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.
BiotechHealthtechParis, FR
Co-investorsHealthCapKurma PartnersNovartis Venture FundRoche Venture FundYsios CapitalColumbus Venture Partners+1 more
HealthtechBoston, US
N. Anthony Coles(Executive Officer, Director)Richard Peters(Executive Officer, Director)Paulash Mohsen(Executive Officer)Brigitte Robertson(Executive Officer)Richard A. Heyman(Director)Jeffery W. Kelly(Director)
Exits · 13
IPOs and acquisitions across the tracked portfolio4D Molecular TherapeuticsNASDAQ: FDMTBolt BiotherapeuticsNASDAQ: BOLTEnliven TherapeuticsNASDAQ: ELVNGinkgo BioworksNYSE: DNAKymera TherapeuticsNASDAQ: KYMRNextCureNASDAQ: NXTCNovoCureNASDAQ: NVCRRhythm PharmaceuticalsNASDAQ: RYTMSynlogicOTC: SYBXvisit ww.nextcure.comNASDAQ: NXTCDVS Sciencesacq. by Fluidigm Corp.ImCheck Therapeuticsacq. by IpsenJnana Therapeuticsacq. by Otsuka
Portfolio news
latest coverage across their companiesRhythm Pharmaceuticals · investing.com · Aug 17, 2026
CytomX · biospace.com · Aug 7, 2026
Arrakis Therapeutics · runtimewire.com · Aug 2, 2026
Resilience · tectonicdefense.com · Jul 17, 2026
visit ww.nextcure.com · investing.com · Jul 15, 2026
Recodetx · geekwire.com · Jul 13, 2026
Merus · finimize.com · Jun 24, 2026
Ginkgo Bioworks · kavout.com · Jun 21, 2026
Frequently asked questions
- How many investments has Pfizer Venture Investments made?
- Pfizer Venture Investments has 186 tracked investments, 5 of which have exited via acquisition or IPO.
- What stage does Pfizer Venture Investments invest at?
- Pfizer Venture Investments invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Pfizer Venture Investments's typical check size?
- Pfizer Venture Investments typically writes checks of $5M – $20M.
- What sectors does Pfizer Venture Investments focus on?
- Pfizer Venture Investments focuses on AI & Machine Learning, Biotech, Healthtech, Medical Devices.
- Does Pfizer Venture Investments lead rounds?
- Yes, Pfizer Venture Investments leads investment rounds.
- Who does Pfizer Venture Investments co-invest with?
- Pfizer Venture Investments most often shares deals with Canaan Partners, RA Capital, OUP (Osage University Partners), among 153 tracked co-investors.
Co-investors · 31
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Andera Partners is an asset management firm specializing in private equity that partners with companies and their management to support sustainable growth. It has backed 377 companies over more than 20 years.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
▶19 more co-investors
Avoro Capital AdvisorsAME Cloud VenturesPolaris PartnersThird Rock VenturesPureos BioventuresRedpoint VenturesHCVCBling CapitalWebb Investment NetworkEarlybird Venture CapitalXtripe AngelsM12 (Microsoft's Venture Fund)EQT Life SciencesForbionThe Column GroupZintinusInnovation WorksRiverfront Ventures, LLCOmega Funds
Firms observed investing alongside Pfizer Venture Investments, from public investor directories. Shared companies are the overlap with Pfizer Venture Investments's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.